← Leaderboards
Stephen C Mack
St. Jude Children'S Research Hospital
$5,806,636
Attributed
$9,750,265
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2021–25$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,750,265 · 6
By mechanism
R01$5,999,716 · 3
U01$3,255,326 · 2
P01$495,223 · 1
Top collaborators
- Benjamin Deneen3 shared
- Giedre Krenciute3 shared
- Timothy N Phoenix3 shared
- Monica Venere3 shared
- Richard W Kriwacki2 shared
Most similar at St. Jude Children'S Research Hospital
Same institution · by research overlap
- Suzanne J Baker$15,879,154
- James M Boyett$5,624,863
- Arzu Onar-Thomas$18,562,079
- Ira J Dunkel$17,198,806
- Richard James Gilbertson$38,555,720
Others in their field
Other Emerging Leaders on “Malignant Neoplasms”
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
- Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
- Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
- Martha Hering · Westat, Inc.$57,098,843
Research focus
Malignant NeoplasmsTumorGenetic TranscriptionCellsBrain NeoplasmsNeoplastic CellMouse ModelInsightBrainMalignant Neoplasm Of BrainProgramsMaintenanceGeneticPathway InteractionsElementsProteinsEpendymomaRecruitIn VivoGene ExpressionOncogenicChromatinChildhood Brain NeoplasmCell Proliferation
Grant awards (16)
Role of FACT in ZFTA-RelA fusion driven ependymoma$691,965
R01 · FY2025 · CA
Transcriptional Regulation in ZFTA-RELA Ependymoma$622,500
R01 · FY2025 · CA · contact PI
Discovering the mechanisms underlying oncogenesis by ZFTA-RELA and pinpointing therapeutic targets.$601,250
U01 · FY2025 · CA · contact PI
Deciphering the Role of Aberrant Endogenous Retroviral Expression in Onco-histone Driven Glioma$518,525
R01 · FY2025 · NS · contact PI
Targeting tumor and T cell DNA methylomes to improve CAR T cell therapies for diffuse midline glioma$498,337
U01 · FY2025 · CA · contact PI
Condensates in Ependymoma$495,223
P01 · FY2025 · CA · contact PI
Targeting tumor and T cell DNA methylomes to improve CAR T cell therapies for diffuse midline glioma$746,809
U01 · FY2024 · CA · contact PI
Role of FACT in ZFTA-RelA fusion driven ependymoma$657,440
R01 · FY2024 · CA
Discovering the mechanisms underlying oncogenesis by ZFTA-RELA and pinpointing therapeutic targets.$601,250
U01 · FY2024 · CA · contact PI
Transcriptional Regulation in ZFTA-RELA Ependymoma$591,375
R01 · FY2024 · CA · contact PI
Deciphering the Role of Aberrant Endogenous Retroviral Expression in Onco-histone Driven Glioma$558,855
R01 · FY2024 · NS · contact PI
Targeting tumor and T cell DNA methylomes to improve CAR T cell therapies for diffuse midline glioma$807,680
U01 · FY2023 · CA · contact PI
Role of FACT in ZFTA-RelA fusion driven ependymoma$720,877
R01 · FY2023 · CA
Transcriptional Regulation in ZFTA-RELA Ependymoma$663,500
R01 · FY2023 · CA · contact PI
Deciphering the Role of Aberrant Endogenous Retroviral Expression in Onco-histone Driven Glioma$576,139
R01 · FY2022 · NS · contact PI
Deciphering the Role of Aberrant Endogenous Retroviral Expression in Onco-histone Driven Glioma$398,540
R01 · FY2021 · NS · contact PI